Tag: chronic lymphocytic leukemia
Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials
Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the 2023 American Society of Hematology (ASH) Annual ... Read More
FDA accepts review of Dr. Reddy’s biosimilar rituximab candidate, DRL_RI
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for a ... Read More
Lilly announces promising results for Pirtobrutinib Phase 1/2 trials
Eli Lilly's oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase ... Read More
BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia
BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib) for the treatment of adult patients with ... Read More
AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL
Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination ... Read More